0.42
0.42 (-0.39%)
As of Jan 17, 2023
Idera Pharmaceuticals, Inc. [IDRA]
Source:
Company Overview
Aceragen, Inc is a clinical-stage biopharmaceutical company with a business strategy focused on the clinical development, and ultimately the commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs.
| Country | United States |
| Headquarters | exton, pennsylvania |
| Phone Number | 4843481600 |
| Industry | manufacturing |
| CEO | John Taylor |
| Website | aceragen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2.5 |
| Operating Profit | $-20.6 |
| Net Income | $-21.9 |
| Net Cash | $-9.9 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -834.3 |
| Profit as % of Revenues | |
| Profit as % of Assets | -24.4% |
| Profit as % of Stockholder Equity | -97% |
Management Effectiveness
| Return on Equity | 1.2% |
| Return on Assets | 0.3% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $78.5 |
| Total Liabilities | $55.9 |
| Operating Cash Flow | $-9.9 |
| Investing Cash Flow | |
| Financing Cash Flow | $-0.1 |
